These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24236974)

  • 1. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
    Aymami J; Barril X; Rodríguez-Pascau L; Martinell M
    Pharm Pat Anal; 2013 Jan; 2(1):109-24. PubMed ID: 24236974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
    Parenti G
    EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
    Haneef SA; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological chaperones as therapeutics for lysosomal storage diseases.
    Boyd RE; Lee G; Rybczynski P; Benjamin ER; Khanna R; Wustman BA; Valenzano KJ
    J Med Chem; 2013 Apr; 56(7):2705-25. PubMed ID: 23363020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement and enhancement therapies for lysosomal diseases.
    Desnick RJ
    J Inherit Metab Dis; 2004; 27(3):385-410. PubMed ID: 15190196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.
    Fan JQ
    Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.
    Valenzano KJ; Khanna R; Powe AC; Boyd R; Lee G; Flanagan JJ; Benjamin ER
    Assay Drug Dev Technol; 2011 Jun; 9(3):213-35. PubMed ID: 21612550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S; Viéitez I; Navarro C; Spuch C
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of lysosomal storage diseases: update and perspectives].
    Lara-Aguilar RA; Juárez-Vázquez CI; Medina-Lozano C
    Rev Invest Clin; 2011; 63(6):651-8. PubMed ID: 23650678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification.
    Keyzor I; Shohet S; Castelli J; Sitaraman S; Veleva-Rotse B; Weimer JM; Fox B; Willer T; Tuske S; Crathorne L; Belzar KJ
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological chaperone therapy for Gaucher disease: a patent review.
    Benito JM; García Fernández JM; Ortiz Mellet C
    Expert Opin Ther Pat; 2011 Jun; 21(6):885-903. PubMed ID: 21457079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclodextrin-based iminosugar click clusters: the first examples of multivalent pharmacological chaperones for the treatment of lysosomal storage disorders.
    Decroocq C; Rodríguez-Lucena D; Ikeda K; Asano N; Compain P
    Chembiochem; 2012 Mar; 13(5):661-4. PubMed ID: 22344719
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent developments in therapeutic approaches for lysosomal storage diseases.
    Urbanelli L; Magini A; Polchi A; Polidoro M; Emiliani C
    Recent Pat CNS Drug Discov; 2011 Jan; 6(1):1-19. PubMed ID: 21073432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression.
    Valayannopoulos V
    Handb Clin Neurol; 2013; 113():1851-7. PubMed ID: 23622408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders.
    Desnick RJ; Schuchman EH
    Nat Rev Genet; 2002 Dec; 3(12):954-66. PubMed ID: 12459725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chaperones as potential therapeutics for Krabbe disease.
    Graziano AC; Pannuzzo G; Avola R; Cardile V
    J Neurosci Res; 2016 Nov; 94(11):1220-30. PubMed ID: 27638605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical and pharmacological chaperones as new therapeutic agents.
    Loo TW; Clarke DM
    Expert Rev Mol Med; 2007 Jun; 9(16):1-18. PubMed ID: 17597553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic approaches for lysosomal storage diseases: a patent update.
    Urbanelli L; Sagini K; Polidoro M; Brozzi A; Magini A; Emiliani C
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):91-109. PubMed ID: 23713988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.